Cellectis' Annual Shareholders General Meeting to be Held on June 28, 2024

Core Points - Cellectis, a clinical-stage biotechnology company, is set to hold its annual general meeting on June 28, 2024, at 2:30 p.m. CET in Paris, France [1] - The company specializes in gene-editing technology to develop cell and gene therapies, particularly focusing on CAR-T immunotherapies for oncology [2] - Cellectis employs an allogeneic approach for CAR-T therapies, aiming to create off-the-shelf gene-edited CAR T-cells for cancer treatment [2] - The company has over 24 years of experience in gene editing and utilizes TALEN® technology and PulseAgile electroporation system [2] Company Overview - Cellectis is headquartered in Paris, France, with additional locations in New York and Raleigh, North Carolina [2] - The company is publicly traded on the Nasdaq Global Market (ticker: CLLS) and Euronext Growth (ticker: ALCLS) [2] - Cellectis focuses on addressing unmet medical needs through innovative gene editing solutions [2]